| Company Name | AbbVie Biopharmaceuticals GmbH Taiwan Branch AbbVie Biopharmaceuticals GmbH Taiwan Branch AbbVie Biopharmaceuticals GmbH Taiwan Branch AbbVie Biopharmaceuticals GmbH Taiwan BranchAbbVie Biopharmaceuticals GmbH Taiwan Branch AbbVie Biopharmaceuticals GmbH Taiwan BranchAbbVie Biopharmaceuticals GmbH Taiwan BranchAbbVie Biopharmaceuticals GmbH Taiwan Branch AbbVie Biopharmaceuticals GmbH Taiwan BranchAbbVie Biopharmaceuticals GmbH Taiwan BranchAbbVie Biopharmaceuticals GmbH Taiwan Branch AbbVie Biopharmaceuticals GmbH Taiwan Branch AbbVie Biopharmaceuticals GmbH Taiwan BranchAbbVie Biopharmaceuticals GmbH Taiwan BranchAbbVie Biopharmaceuticals GmbH Taiwan Branch AbbVie Biopharmaceuticals GmbH Taiwan Branch AbbVie Biopharmaceuticals GmbH Taiwan BranchAbbVie Biopharmaceuticals GmbH Taiwan BranchAbbVie Biopharmaceuticals GmbH Taiwan BranchAbbVie Biopharmaceuticals GmbH Taiwan Branch AbbVie |
|---|---|
| Protocol Number | P15-778 |
| Title of Study | Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan |
| Primary Objective | The objective of this non-interventional, observational study is to assess the impact of adalimumab on health-related QoL and work productivity in patients with Rheumatoid Arthritis (RA) in Taiwan |
| Number of Sites | 7 |
| Period of Study | From：Aug. 24, 2015 to：Dec. 31, 2017 |
| Number of Patients | 100人 |
| IRB Approval Date | July 9, 2015 |
| Publication Plan / Date | Sep., 2018 |
